Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=164 Tools For Teen Moms: Reducing Infant Obesity Risk
Adolescent Mothers · Infant Obesity
Primary: Change in Infant Growth — -0.46; -0.44; -0.33; -0.46 Weight for age Z-score
Phase 3 N=34 Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children
Spinal Puncture
Primary: Duration of Apnea — 110; 73 seconds
N/A N=328 Randomized Trial to Test the "Coordinated Care for Health Promotion and Activities in Parkinson's Disease" Intervention in the VA
Parkinson Disease
Primary: Proportion of Measures Adhered To in the PD Guidelines — 0.77; 0.58 proportion of quality measures followed — p=>0.05
Phase 1 N=8 A Study of LY2605541 Versus Insulin Glargine on Blood Sugar
Healthy Volunteers · Diabetes Mellitus, Type 1
Primary: Part B: Glucodynamics: Endogenous Glucose Output — 64.53; 99.23; 78.05; 97.05 percent of suppression
Phase 1 N=12 Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State
Healthy Volunteers
Primary: Maximum Measured Concentration of Idarucizumab in Plasma (Cmax) — 30900 nanomoles (nmol) per litre (L)
N/A N=3,182 SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
Atrial Fibrillation
Primary: Occurrence of Adverse Events(Including Unexpected Adverse Events, Serious Adverse Events, Drug-related Adverse Events, Adverse Events Leading to Discontinuation and…
Phase 1 N=30 The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞]) of LY2409021 — 34700; 35300; 38000; 145000 nanogram*hours per milliliter (ng*h/mL)
Phase 3 N=216 Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)
Anesthesia
Primary: Number of Participants With Body Movement During Anesthetic Maintenance — 165; 111; 54; 50 participants
N/A N=481 Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation
Mental Disorders
Primary: Shared Decision Making (OPTION) Independent Blind Coder Assessment Scores — 36.31; 29.78; 34.50; 30.37 units on a scale
N/A N=13 Sensory Stimulation During CIMT
Cerebral Palsy
Primary: Feasibility (Total Number of Hours That Participants Wear the Device) — 28.3; 27.9 Hours
Phase 3 N=530 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Urothelial Carcinoma
Primary: Progression Free Survival (PFS) — 4.07; 2.76 Months — p=0.0118
Phase 2 N=327 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) — 2.8; 2.9 months — p=0.761
Phase 1 N=72 A Study of LY2484595 on the Electrical Activity of the Heart
Healthy Volunteers
Primary: Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo — -2.7; -4.6; -2.0; -1.1 milliseconds (msec)
Phase 4 N=127 Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers
Tobacco Use Disorder · Homelessness
Primary: Number of Participants Self-reported and Bioverified Abstinent From Smoking — 13; 5 Participants